Collaborating with multinational liver societies, patient advocacy groups, and leading experts and researchers, a global consortium will unveil a new nomenclature for the prevalent Non-Alcoholic Fatty Liver Disease (NAFLD) at the upcoming EASL Congress in Vienna on 21-24 June. This…
The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. This novel combinatorial therapy is called G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and…
MICROB-PREDICT aims to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual…
Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from the European Federation of Pharmaceutical Industries and Associations…
EASL is pleased to announce the release of the EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma to coincide with the EASL Liver Cancer Summit 2023. Intrahepatic cholangiocarcinoma (iCCA) represents the second most frequent primary liver cancer after…
Join the global movement. Celebrate World Liver Day with us on 19 April 2023! We are excited to announce World Liver Day, taking place TODAY, 19 April 2023. This global movement led by the European Association for the Study of the Liver (EASL),…
Dear colleagues and friends: We have to share the sad news that Peter Ferenci has passed away on 11 April 2023 just a few weeks before his 75th birthday. He recently celebrated his 50 years anniversary at the Medical University…
The European Association for the Study of the Liver (EASL) and the Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) have issued a joint statement on metabolic dysfunction-associated fatty liver disease (MAFLD), now available for consultation. This statement provides clear…
Are you ready to boost your leadership skills in EASL’s governance? EASL is now looking to fill the following positions: Vice-Secretary Treasurer Public Health Councillor One Scientific Committee Member Two Young Investigators Task Force Members Two Nurses & AHPs Task Force Members
The EASL Congress 2023 is around the corner, and we are looking for our next awardees to celebrate.